Sign in

BSPK

Bespoke Extracts, Inc.

Bespoke Extracts, Inc. is an American pharmaceutical preparations company based in Aurora.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with China SXT Pharmaceuticals, Inc., Matinas BioPharma Holdings, Inc. or Neuphoria Therapeutics Inc., or pick any stock.

  • TickerBSPK1
  • IndustryPharmaceutical Preparations1
  • HeadquartersAurora, Colorado1
  • Incorporated inNV2
  • Business address12001 E. 33Rd St- Unit O, Aurora, Co 800102
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

DutchBlunts, and Wee Joints , to licensed marijuana dispensaries across Colorado.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

40.5%Gross margin4
-89.0%Operating margin4
-92.8%Net margin4
42.3%Revenue growth, 20244
-$889.8KFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue34¢$664.5K
  • Selling, general and admin66¢$1.3M

Out of $1.1M in revenue.4 The company lost money this year.

Financial statements

Revenue5674$1.1M in 2024+6920% since 2018
0$500.0K$1.0M$1.5M2018: $15.9K$15.9K20182019: $62.1K$62.1K2019+290%2021: $35.6K$35.6K2021−43%2022: $3.4K$3.4K2022−90%2023: $785.5K$785.5K2023+22954%2024: $1.1M$1.1M2024+42%
Gross profit589674$452.9K in 2024
-$200.0K0$200.0K$400.0K$600.0K2018: -$7.0K-$7.0K20182019: -$9.3K-$9.3K2019+33%2020: $4.5K$4.5K20202021: $22.0K$22.0K2021+384%2022: $2.3K$2.3K2022−90%2023: $343.2K$343.2K2023+15098%2024: $452.9K$452.9K2024+32%
Operating income589674-$994.6K in 2024−86% since 2018
-$10.0M-$5.0M0$5.0M2018: -$7.2M-$7.2M20182019: $3.0M$3.0M20192020: -$4.0M-$4.0M20202021: -$965.6K-$965.6K2021−76%2022: -$4.0M-$4.0M2022+316%2023: -$1.5M-$1.5M2023−63%2024: -$994.6K-$994.6K2024−32%
Net income589674-$1.0M in 2024−86% since 2018
-$10.0M-$5.0M0$5.0M2018: -$7.6M-$7.6M20182019: $2.6M$2.6M20192020: -$4.6M-$4.6M20202021: -$965.6K-$965.6K2021−79%2022: -$4.1M-$4.1M2022+326%2023: -$1.5M-$1.5M2023−64%2024: -$1.0M-$1.0M2024−30%
Fiscal year2018201920202021202220232024
Revenue$15.9K5$62.1K5$35.6K6$3.4K7$785.5K4$1.1M4
Cost of revenue$22.9K5$71.4K8$3.5K9$13.6K6$1.1K7$442.3K4$664.5K4
Gross profit-$7.0K5-$9.3K8$4.5K9$22.0K6$2.3K7$343.2K4$452.9K4
Selling, general and admin$6.8M5-$3.5M5$640.9K6$3.7M7$1.6M4$1.3M4
Operating expenses$4.0M7$1.8M4$1.4M4
Operating income-$7.2M5$3.0M8-$4.0M9-$965.6K6-$4.0M7-$1.5M4-$994.6K4
Interest$419.0K5$357.5K8$535.7K9
Income before tax-$4.1M7-$1.5M4-$1.0M4
Net income-$7.6M5$2.6M8-$4.6M9-$965.6K6-$4.1M7-$1.5M4-$1.0M4
Earnings per share-$0.215$0.045-$0.196-$0.447-$0.154-$0.104
Earnings per share (diluted)-$0.215$0.045-$0.196-$0.447-$0.154-$0.104
Shares (weighted, basic)9.4M shares710.2M shares410.5M shares4
Shares (weighted, diluted)9.4M shares710.2M shares410.5M shares4

Compare Bespoke Extracts, Inc. with another company

Corporate structure

Bespoke Extracts, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Bespoke Extracts, Inc.

  • Michael Feinsod Filed SC 13D/A on Bespoke Extracts, Inc., latest Apr 15, 2022 (3 filings since Nov 29, 2021)
  • Tyler Hunter Garth Filed SC 13D on Bespoke Extracts, Inc., latest Dec 16, 2021
  • Danil Pollack Filed SC 13D/A on Bespoke Extracts, Inc., latest Nov 23, 2021
  • Bespoke Extracts, Inc. Aurora, Colorado

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Bespoke Extracts, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Furniture and fixtures$41.0K7 Dec 31, 2023$9.9K7 Dec 31, 2022+312.0%
Property and equipment, before depreciation$49.9K4 Dec 31, 2024$49.9K4 Dec 31, 20230%
Accumulated depreciation$18.6K4 Dec 31, 2024$9.0K4 Dec 31, 2023+107.5%
Property and equipment, net$31.3K4 Dec 31, 2024$41.0K4 Dec 31, 2023−23.5%
Operating-lease assets (leased space)$140.5K4 Dec 31, 2024$209.5K4 Dec 31, 2023−33.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.6K7 Dec 31, 2023$24.4K7 Dec 31, 2022−73.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Licenses, net$10.0K4 Dec 31, 2024$10.0K4 Dec 31, 20230%

Inventory

ItemLatestA year beforeChange
Inventory, total$32.5K4 Dec 31, 2024$15.8K4 Dec 31, 2023+105.9%
Raw materials$32.5K4 Dec 31, 2024$15.8K4 Dec 31, 2023+105.9%
Finished goods$07 Dec 31, 2023$07 Dec 31, 2022

Properties, in its own words

We maintain our principal office at 12001 E. 33rd Avenue, Unit O, Aurora, CO., under a 5-year lease that commenced December 2021 (with an option to renew for an additional five-year term). Monthly rent started at $6,000. We believe that our existing facilities are suitable and adequate to meet our current business requirements. The lease contains an option to purchase the property for $600,000. Effective December 31, 2024, we entered amended the lease to provide for monthly rent of $4,000 through the term of the lease.

Item 2 of the 10-K filed Apr 21, 2025.3

Leadership

Who has led Bespoke Extracts, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Barry Tenzer2011–2017
  2. Marc Yahr2017
  3. Niquana Monique Noel2018–2019
  4. Danil Pollack2020–2021
  5. Michael Feinsod2021–now

President

  1. Barry Tenzer2011–2017
  2. Marc Yahr2017
  3. Niquana Monique Noel2018–2019
  4. Danil Pollack2020
  5. Tyler Hunter Garth2021–now

Chief financial officer

  1. Barry Tenzer2011–2017
201520202025
Board members and other officers (9)

Former names

  • DiMi Telematics International, Inc.Apr 16, 2012 to Feb 8, 20172
  • First Quantum Ventures IncNov 13, 2007 to Mar 19, 20122

Timeline

  1. Jul 6, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares24
  2. Nov 19, 20258-K Results of operations25
  3. Oct 8, 20258-K Entered a material agreement26
  4. Jul 7, 20258-K Results of operations27
  5. May 9, 20258-K Change of auditor28
  6. Feb 19, 20258-K Entered a material agreement; New debt or obligation29
  7. Dec 26, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares30
  8. Feb 20, 20248-K Entered a material agreement; New debt or obligation; Unregistered sale of shares31
  9. Jan 9, 20238-K Completed an acquisition or sale32
  10. Nov 16, 20228-K Entered a material agreement33
  11. Nov 7, 20228-K Change of auditor34
  12. Nov 3, 20228-K Entered a material agreement35
  13. Nov 29, 2021New chief executive Michael Feinsod becomes CEO14
  14. Apr 29, 2020New chief executive Danil Pollack becomes CEO15
  15. Nov 6, 2018New chief executive Niquana Monique Noel becomes CEO16
  16. Jun 1, 2017New chief executive Marc Yahr becomes CEO17
  17. Nov 18, 2011New chief executive Barry Tenzer becomes CEO18

Calendar

When it reported results

  1. Nov 19, 2025Reported quarterly or annual results25
  2. Jul 7, 2025Reported quarterly or annual results27

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

107 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 24 major events, 37 insider forms, 5 large holders, 2 private raises, 21 other. The latest 20:

  1. Aug 17, 2026NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  2. Jul 6, 20268-K CURRENT REPORT EDGAR
  3. May 18, 2026NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  4. Mar 31, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
  5. Jan 8, 20265 EDGAR
  6. Jan 8, 20264 EDGAR
  7. Nov 19, 20258-K CURRENT REPORT EDGAR
  8. Nov 12, 202510-Q QUARTERLY REPORT EDGAR
  9. Oct 8, 20258-K CURRENT REPORT EDGAR
  10. Sep 11, 20254 EDGAR
  11. Sep 8, 20254 EDGAR
  12. Sep 5, 20254 EDGAR
  13. Aug 27, 202510-Q QUARTERLY REPORT EDGAR
  14. Aug 14, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  15. Jul 7, 20258-K CURRENT REPORT EDGAR
  16. Jul 3, 20254 EDGAR
  17. Jun 30, 202510-Q QUARTERLY REPORT EDGAR
  18. May 15, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  19. May 12, 20254 EDGAR
  20. May 9, 20258-K CURRENT REPORT EDGAR

The 107 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

45 open-market trades by officers, directors and large owners since October 2021: 44 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 11, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy1,500$0.27$405Form 4
Sep 10, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy2,000$0.19$380Form 4
Sep 8, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy2,500$0.19$475Form 4
Sep 5, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy2,500$0.20$500Form 4
Jul 2, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy8,000$0.11$880Form 4
May 12, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy1,000$0.10$100Form 4
May 9, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy1,000$0.11$110Form 4
Jan 31, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy2,000$0.11$220Form 4
Jan 30, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy1,000$0.11$110Form 4
Jan 23, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy3,500$0.10$350Form 4
Jan 22, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy4,500$0.11$495Form 4
Jan 3, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy4,500$0.10$450Form 4
Jan 2, 2025FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy8,500$0.11$935Form 4
Nov 14, 2024FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy1,500$0.19$285Form 4
Nov 12, 2024FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy2,500$0.16$400Form 4
Sep 9, 2024FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy500$0.13$65Form 4
Sep 6, 2024FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy1,500$0.11$165Form 4
Aug 28, 2024FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy2,000$0.09$180Form 4
Aug 27, 2024FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy3,000$0.09$270Form 4
Aug 2, 2024FEINSOD MICHAELCHIEF EXECUTIVE OFFICERBuy1,500$0.08$120Form 4

All 45 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 16, 2024Raised $100,000 in a private offering of debt Form D: $1 million offered in all Form D
  2. Dec 27, 2021Raised $250,000 in a private offering of equity Form D: $1 million offered in all Form D

SEC filer profile

How Bespoke Extracts, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBespoke Extracts, Inc.1
  • CIK0001409197
  • Employer ID (EIN)20-47433543
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inNevada3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address12001 E. 33Rd St- Unit O, Aurora, CO 800101
  • Phone720-949-11431
  • Shares outstanding11,253,552 as of Nov 10, 202512
  • Public float$760.0K as of Jun 30, 20243
  • AuditorASSURANCE DIMENSIONS, LLC, Coral Springs, Florida PCAOB ID 5036; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceAug 10, 20071
  • Filings350 in all: 8-K (90), 10-Q (53), 4 (50), NT 10-Q (32), 10-K (17), NT 10-K (15), UPLOAD (13), SC 13D/A (12)1
    All 29 form types

    3 (10), SC 13D (9), 8-K/A (6), 10-K/A (5), 10-Q/A (5), DEF 14C (5), PRE 14C (5), SC 14F1 (5), 10QSB (3), CORRESP (3), D (2), 10-QT (1), 10QSB/A (1), 10SB12G (1), 4/A (1), 5 (1), NT 10-K/A (1), NT 10-Q/A (1), NTN 10K (1), NTN 10Q (1), SC 14F1/A (1)

  • Latest filingsAnnual report (10-K) Apr 21, 2025
    Quarterly report (10-Q) Nov 12, 2025
    Latest 8-K (8-K) Jul 6, 2026

Risk factors and legal proceedings

The risks Bespoke Extracts, Inc. names in Item 1A of its 10-K filed Apr 21, 2025: 34 risks under these headings, as written.3

  • Risk Related to our Business and Industry
  • We have a history of operating losses, have a working capital deficit as of December 31, 2024, and we may not achieve or maintain profitability in the future.
  • We will need to raise additional capital, which may not be available.
  • We have a limited operating history that impedes our ability to evaluate our potential future performance and strategy.
  • Our operating results may fluctuate significantly based on customer acceptance of our products. As a result our period-to-period comparisons of our results of operations are unlikely to provide a good indication of our future performance.
  • If we do not successfully develop and commercialize additional products, we could lose revenue opportunities.
  • We may have difficulties managing our Company’s growth, which could lead to higher operating losses, or we may not grow at all.
  • Loss of our chief executive officer or president could limit our growth and negatively impact our operations.
  • We will be required to attract and retain top quality talent to compete in the marketplace.
  • Our inability to effectively protect our intellectual property would adversely affect our ability to compete effectively, our revenue, our financial condition, and our results of operations.
  • Our industry is highly competitive, and we have less capital and resources than many of our competitors, which may give them an advantage in developing and marketing products similar to ours or make our products obsolete.
  • The COVID-19 pandemic may negatively affect our business.
The other 23 risks
  • We may be subject to the risks associated with future acquisitions , which may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
  • Cannabis remains illegal under federal law.
  • Our business is dependent on state laws pertaining to the cannabis industry.
  • We are required to comply concurrently with federal, state and local laws in each jurisdiction where we operate or to which we sell our products.
  • We are or will be subject to risks related to unsafe concentration of heavy metals and other contaminants in our cannabis and nutrient products, and associated inconsistent treatment under state law.
  • Newly Established and Developing Legal Regimes
  • Federal Regulation of Hemp-Based CBD & THC
  • We will be subject to risks inherent in an agricultural business, including the risk of crop failure.
  • The cannabis industry and market are relatively new in the United States, and this industry and market may not continue to exist or develop as anticipated or we may ultimately be unable to succeed in this industry and market.
  • We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception.
  • Certain events or developments in the cannabis industry more generally may impact our reputation.
  • The cannabis industry could face strong opposition from other industries.
  • Businesses involved in the cannabis industry, and investments in such businesses, are subject to a variety of laws and regulations related to money laundering, financial recordkeeping and proceeds of crimes.
  • We may be unable to seek the protection of the bankruptcy courts.
  • Risks Related to our Common Stock
  • There is a limited trading market for our common stock, and investors may find it difficult to buy and sell our shares.
  • The market price of our common stock is, and is likely to continue to be, highly volatile and subject to wide fluctuations.
  • Our common stock is considered a “penny stock” and is subject to additional sale and trading regulations that may make it more difficult to buy or sell.
  • We do not intend to pay dividends on our common stock for the foreseeable future.
  • Our chief executive officer beneficially owns the majority of the voting power of our shareholders.
  • Additional stock offerings in the future may dilute then-existing shareholders’ percentage ownership of the Company.
  • We are subject to increased costs as a result of being a public company
  • We face costs of maintaining a public listing.
  • The rights of the holders of common stock may be impaired by the potential issuance of preferred stock.
  • Failure to achieve and maintain internal controls in accordance with Sections 302 and 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price.

Legal proceedings

We are not party to, and our property is not the subject of, any material legal proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38